Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) - PT009001

Exclusion Criteria

• -Significant diseases other than COPD, ie., disease or condition which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study
• -Pregnancy, nursing female subjects, or subjects trying to conceive, or not using medically acceptable form of contraception
• -Asthma: Subjects who have a primary diagnosis of asthma (Note: Subjects with a prior history of asthma are eligible if COPD is currently their primary diagnosis).
• -Alpha 1 Antitrypsin Deficiency: Subjects who have alpha 1 antitrypsin deficiency as the cause of COPD
• -Active pulmonary disease such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung disease, and uncontrolled sleep apnea (ie., in the opinion of the Investigator severity of the disorder would impact the conduct of the study)-
• -Clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study
• -Poorly Controlled COPD
• -History of ECG abnormalities
• -Cancer not in complete remission for at least 5 years
• -Clinically significant, symptomatic prostatic hypertrophy
• -Male subjects with a trans-urethral resection of the prostate or full resection of the prostate within 6 months prior to Screening
• -Clinically significant bladder neck obstruction or urinary retention
• -Inadequately treated glaucoma
• -History of an allergic reaction or hypersensitivity to any drug or to any component of the formulations used in this study